Bisphosphonates: The first 40 years

Bone

Volumn 49, Issue 1, 2011, Pages 2-19

  Russell, R Graham G ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bisphosphonates; Bone metastases; Bone resorption; Hydroxyapatite; Osteoclasts; Osteoporosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CHOLESTEROL; CLODRONIC ACID; ETIDRONIC ACID; FARNESOL; GENERIC DRUG; GERANYLGERANIOL; GERANYLTRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; HYDROXYAPATITE; IBANDRONIC ACID; INCADRONIC ACID; ISOPENTENYL DIPHOSPHATE; MEVALONIC ACID; MINODRONIC ACID; NITROGEN; OLPADRONIC ACID; PAMIDRONIC ACID; PYROPHOSPHORIC ACID DERIVATIVE; RAB PROTEIN; RAC PROTEIN; RHO FACTOR; RISEDRONIC ACID; TILUDRONIC ACID; UNINDEXED DRUG; ZOLEDRONIC ACID;

BIOSYNTHESIS; BONE CANCER; BONE DISEASE; BONE MINERAL; BONE MINERALIZATION; CALCIFICATION; CHOLESTEROL SYNTHESIS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYDROLYSIS; METABOLIC BONE DISEASE; NONHUMAN; OSSIFYING MYOSITIS; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PHYSICAL CHEMISTRY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; DIPHOSPHATES; DIPHOSPHONATES; HUMANS; MODELS, BIOLOGICAL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79958695940     PISSN: 87563282     EISSN: 87563282     Source Type: Journal    
DOI: 10.1016/j.bone.2011.04.022     Document Type: Review

References (240)

1. Menschutkin N. Ueber die Einwirkung des Chloracetyls auf phosphorige Saure. Ann Chem Pharmacol 1865, 133:317-320.
2. Von Baeyer H., Hofmann K.A. Acetodiphosphorige Saure. Berichte Dtsch Chem Ges 1897, 20:1973-1978.
3. Blomen L.J.M.J. Discovery and history of the non-medical uses of bisphosphonates. Chapter 7. Bisphosphonates on bone 1995, 111-124. Elsevier Science B.V. O. Bijvoet, H.A. Fleisch, R.E. Canfield, R.G.G. Russell (Eds.).
4. Russell R.G., Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999, 25:97-106. [Review].
5. Fleisch H. Bisphosphonates in bone disease. From the laboratory to the patient 2000, Academic Press. Fourth Edition.
6. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998, 19(1):80-100.
7. Green J.R. Bisphosphonates: preclinical review. Oncologist 2004, 9(Suppl 4):3-13. [Review].
8. Geddes A.D., D'Souza S.M., Ebetino F.H., Ibbotson K.J. Bisphosphonates: structure-activity relationships and therapeutic implications. Bone Miner Res 1994, 8:265-306.
9. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996 Feb, 18(2):75-85. [Review].
10. Roelofs AJ, Ebetino FH, Reska AA, Russell R.G.G, Rogers MJ. Bisphosphonates. Mechanisms of Action. Chapter 81 In 'Principles of Bone Biology' 3rd edition, San Diego: Academic Press, Ed Bilizekian J; 2008.
11. Bisphosphonates on bone 1995, Elsevier Science B.V. O. Bijvoet, H. Fleisch, R.E. Canfield, R.G.G. Russell (Eds.).
12. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
13. Neuman William F., Margaret W. The chemical dynamics of bone mineral 1958, The University of Chicago Press, Chicago.
14. Fleisch H., Neuman W.F. Mechanisms of calcification: role of collagen, polyphosphates, and phosphatase. Am J Physiol 1961, 200:1296-1300.
15. Fleisch H., Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 1962, 203:671-675.
16. Russell R.G.G., Hodgkinson A. The urinary excretion of inorganic pyrophosphate by normal subjects and patients with renal calculus. Clin Sci 1966, 31:51-62.
17. Russell R.G.G. Excretion of inorganic pyrophosphate in hypophosphatasia. Lancet 1965, ii:461-464.
18. Russell R.G.G., Bisaz S., Donath A., Morgan D.B., Fleisch H. Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta and other disorders of bone. J Clin Invest 1971, 50:961-969.
19. Fleisch H., Russell R.G.G., Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966, 212:901-903.
20. Jung A., Bisaz S., Gebauer U., Russell R.G.G., Morgan D.B., Fleisch H. The uptake and metabolism of 32P-pyrophosphate by mouse calvaria in vitro. Biochem J 1974, 140:175-183.
21. Burnstock G., Verkhratsky A. Evolutionary origins of the purinergic signalling system. Acta Physiol (Oxf) Apr 2009, 195(4):415-447. [Epub 2009 Feb 12. Review].
22. Orriss I.R., Burnstock G., Arnett T.R. Purinergic signalling and bone remodelling. Curr Opin Pharmacol Jun 2010, 10(3):322-330. [Epub 2010 Feb 25. Review].
23. Abhishek A., Doherty M. Pathophysiology of articular chondrocalcinosis-role of ANKH. Nat Rev Rheumatol Feb 2011, 7(2):96-104. [Epub 2010 Nov 23].
24. Collins M.T., Boehm M. It ANKH necessarily so. J Clin Endocrinol Metab Jan 2011, 96(1):72-74.
25. Terkeltaub R.A. Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol Jul 2001, 281(1):C1-C11. [Review].
26. Anderson H.C., Harmey D., Camacho N.P., Garimella R., Sipe J.B., Tague S., et al. Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am J Pathol 2005, 166:1711-1720.
27. Timms A., Zhang Y., Russell R.G.G., Brown M. Genetic studies of disorders of calcium crystal deposition. Rheumatology (Oxford) 2002, 41:725-729.
28. Mumm S., Jones J., Finnegan P., Whyte M.P. Hypophosphatasia: molecular diagnosis of Rathbun's original case. J Bone Miner Res Sep 2001, 16(9):1724-1727.
29. Fedde K.N., Blair L., Silverstein J., Coburn S.P., Ryan L.M., Weinstein R.S., et al. Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res Dec 1999, 14(12):2015-2026.
30. Mornet E. Hypophosphatasia: the mutations in the tissue-nonspecific alkaline phosphatase gene. Hum Mutat 2000, 15(4):309-315. [Review].
31. Whyte M.P. Physiological role of alkaline phosphatase explored in hypophosphatasia. Ann NY Acad Sci Mar 2010, 1192:190-200. [Review].
32. Ruf N., Uhlenberg B., Terkeltaub R., Nurnberg P., Rutsch F. The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). Hum Mutat 2005, 25:98.
33. Nakamura I., Ikegawa S., Okawa A., Okuda S., Koshizuka Y., Kawaguchi H., et al. Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). Hum Genet 1999, 104:492-497.
34. Ho A.M., Johnson M.D., Kingsley D.M. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000, 289:265-270.
35. Williams C.J., Zhang Y., Timms A., Bonavita G., Caeiro F., Broxholme J., et al. Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH. Am J Hum Genet Oct 2002, 71(4):985-991.
36. Zhang Y., Johnson K., Russell R.G., Wordsworth B.P., Carr A.J., Terkeltaub R.A., et al. Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate. Arthritis Rheum 2005, 52:1110-1117.
37. Pendleton A., Johnson M.D., Hughes A., Gurley K.A., Ho A.M., Doherty M., et al. Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 2002, 71:933-940.
38. Reichenberger E., Tiziani V., Watanabe S., Park L., Ueki Y., Santanna C., et al. Autosomal dominant craniometaphyseal dysplasia is caused mutations in the transmembrane protein ANK. Am J Hum Genet 2001, 68:1321-1326.
39. Nuernberg P., Thiele H., Chandler D., Hohne W., Cunningham M.L., Ritter H., et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 2001, 28:37-41.
40. Prontera P., Rogaia D., Sobacchi C., Tavares V.L., Mazzotta G., Passos-Bueno M.R., et al. Craniometaphyseal dysplasia with severe craniofacial involvement shows homozygosity at 6q21-22.1 locus. Am J Med Genet A May 2011, 155(5):1106-1108. [Epub 2011 Apr 4]. 10.1002/ajmg.a.33826.
41. Morava E., Kühnisch J., Drijvers J.M., Robben J.H., Cremers C., van Setten P., et al. Autosomal recessive mental retardation, deafness, ankylosis, and mild hypophosphatemia associated with a novel ANKH mutation in a consanguineous family. J Clin Endocrinol Metab Jan 2011, 96(1):E189-E198. [Epub 2010 Oct 13].
42. Markello T.C., Pak L.K., St Hilaire C., Dorward H., Ziegler S.G., Chen M.Y., et al. Vascular pathology of medial arterial calcifications in NT5E deficiency: implications for the role of adenosine in pseudoxanthoma elasticum. Mol Genet Metab May 2011, 103(1):44-50. [Epub 2011 Feb 3].
43. St Hilaire C., Ziegler S.G., Markello T.C., Brusco A., Groden C., Gill F., et al. NT5E mutations and arterial calcifications. N Engl J Med Feb 3 2011, 364(5):432-442.
44. Schibler D., Russell R.G.G., Fleisch H. Inhibition by pyrophosphate of aortic calcification induced by Vitamin D3 in rats. Clin Sci 1968, 35:363-372.
45. Jung A., Bisaz S., Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 1973, 11:269-280.
46. Fleisch H.A., Russell R.G.G., Bisaz S., Muehlbauer R.C., Williams D.A. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1970, 1:12-18.
47. Schenk R., Merz W.A., Muehlbauer R., Russell R.G.G., Fleisch H. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 1973, 11:196-214.
48. Fleisch H., Maerki J., Russell R.G.G. Effect of pyrophosphate on dissolution of hydroxyapatite and its possible importance in calcium homeostasis. Proc Soc Exp Biol 1966, 122:317-320.
49. Russell R.G.G., Muhlbauer R.C., Bisaz S., Williams D.A., Fleisch H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 1970, 6:83-196.
50. Fleisch H., Russell R.G.G., Bisaz S., Casey P.A., Muehlbauer R.C. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif Tissue Res 1968, 2:10-10A.
51. Fleisch H., Russell R.G., Bisaz S., Mühlbauer R. Influence of diphosphonates on the deposition and dissolution of calcium phosphate in vitro and in vivo. Helv Physiol Pharmacol Acta 1968, 26(3):CR345-6. [German].
52. Francis M.D., Russell R.G.G., Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969, 165:1264-1266.
53. Fleisch H., Russell R.G.G., Francis M.D. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969, 165:1262-1264.
54. Francis M.D., Briner W.W. The effect of phosphonates on dental enamel in vitro and calculus formation in vivo. Calcif Tissue Res Jan 25 1973, 11(1):1-9.
55. Francis M.D. The inhibition of calcium hydroxypatite crystal growth by polyphosphonates and polyphosphates. Calcif Tissue Res 1969, 3(2):151-162.
56. Tofe A.J., Francis M.D. Optimization of the ratio of stannous tin: ethane-1-hydroxy-1, 1-diphosphonate for bone scanning with 99mTc-pertechnetate. J Nucl Med Feb 1974, 15(2):69-74.
57. Muehlbauer R.C., Russell R.G.G., Williams D.A., Fleisch H. The effects of diphosphonates, polyphosphates and calcitonin on immobilisation osteoporosis in rats. Eur J Clin Invest 1971, 1:336-344.
58. Fleisch H., Russell R.G.G., Simpson B., Muhlbauer R.C. Prevention by a diphosphonate of immobilisation 'osteoporosis' in rats. Nature 1969, 223:211-212.
59. Minaire P., Depassio J., Berard E., Meunier P.J., Edouard C., Pilonchery G., et al. Effects of clodronate on immobilization bone loss. Bone 1987, 8(Suppl 1):S63-S68. [Review].
60. Schenk R., Merz W.A., Muhlbauer R., Russell R.G.G., Fleisch H. Effect of two diphosphonates on bone and cartilage growth and resorption in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 1973, 11:196-214.
61. Schenk R., Eggli P., Fleisch H., Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986, 38:342-349.
62. Lundy M.W., Ebetino F.H., Fei L., Xia Z., Pozzi M., Trokhan D., et al. Bisphosphonate affinity to hydroxyapatite and farnesyl pyrophosphate inhibitory potency together drive in vivo efficacy. J Bone Miner Res 2007, 22(Suppl 1):S443.
63. Gasser A.B., Morgan D.B., Fleisch H.A., Richelle L.J. The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci 1972, 43:31-45.
64. Trechsel U., Stutzer A., Fleisch H. Hypercalcaemia induced with an arotinoid in thyroparathyroidectomised rats. a new model to study bone resorption in vivo. J Clin Invest 1987, 80:1679-1686.
65. Stutzer A., Fleisch H., Trechsel U. Short and long term effects of a single dose of bisphosphonates on retibnoid-induced bone resorption in thyroparathyroidectomised rats. Calcif Tissue Int 1988, 43:294-299.
66. Muehlbauer R.C., Bauss F., Schenk R., Janner M., Boises E., Strein K., et al. BM21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991, 6:1003-1011.
67. Widler L., Jaeggi K.A., Glatt M., Müller K., Bachmann R., Bisping M., et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002, 45:3721-3738.
68. Cremers S., Papapoulos S. Pharmacology of bisphosphonates. Bone Jan 31 2011-this issue.
69. Green J.R., Müller K., Jaeggi K.A. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994, 9(5):745-751.
70. Ferretti J.L. Effects of bisphosphonates on bone biomechanics. Chapter 31. Bisphosphonates on bone 1995, Elsevier Science B.V. O. Bijvoet, H.A. Fleisch, R.E. Canfield, R.G.G. Russell (Eds.).
71. Borah B., Ritman E.L., Dufresne T.E., Jorgensen S.M., Liu S., Sacha J., et al. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 2005, 37(1):1-9.
72. Guy J.A., Shea M., Peter C.P., Morrissey R., Hayes W.C. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int. 1993, 53(4):283-288.
73. Lalla S., Hothorn L.A., Haag N., Bader R., Bauss F. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos Int 1998, 8:97-103.
74. Bauss F., Lalla S., Endele R., Hothorn L.A. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol 2002, 29:2200-2208.
75. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294-1301.
76. Ott S.M. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005, 90:1897-1899.
77. Mashiba T., Mori S., Burr D.B., Komatsubara S., Cao Y., Manabe T., et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005, 23(Suppl):36-42.
78. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613-620.
79. Flora L., Hassing G.S., Cloyd G.G., Bevan J.A., Parfitt A.M., Villanueva A.R. The long-term skeletal effects of EHDP in dogs. Metab Bone Dis Relat Res 1981, 3(4-5):289-300.
80. Allen M.R., Burr D.B. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 2010.
81. Allen M.R., Turek J.J., Phipps R.J., Burr D.B. Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate. Bone 2010.
82. Bauss F., Schenk R.K., Hort S., Muller-Beckmann B., Sponer G. New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J Pharmacol Toxicol Methods 2004, 50:25-34.
83. Bobyn J.D., Hacking S.A., Krygier J.J., Harvey E.J., Little D.G., Tanzer M. Zoledronic acid causes enhancement of bone growth into porous implants. J Bone Joint Surg Br 2005, 87:416-420.
84. Little D.G., McDonald M., Bransford R., Godfrey C.B., Amanat N. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res 2005, 20:2044-2052.
85. Wilkinson J.M., Little D.G. Bisphosphonates in orthopedic applications. Bone 2011.
86. Wilkinson J.M., Eagleton A.C., Stockley I., Peel N.F., Hamer A.J., Eastell R. Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial. J Orthop Res 2005, 23:1-8.
87. Aspenberg P. Bisphosphonates and implants. An overview. Acta Orthop 2009, 80(1):119-123.
88. Javed F., Almas K. Osseointegration of dental implants in patients undergoing bisphosphonate treatment: a literature review. J Periodontol 2010, 81(4):479-484. [Review].
89. Kurth A.H., Eberhardt C., Müller S., Steinacker M., Schwarz M., Bauss F. The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. Bone 2005, 37:204-210.
90. Little D.G., Smith N.C., Williams P.R., Briody J.N., Bilston L.E., Smith E.J., et al. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 2003, 18:1300-1307.
91. Little D.G., Peat R.A., Mcevoy A., Williams P.R., Smith E.J., Baldock P.A. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res 2003, 18:2016-2022.
92. Lai K.A., Shen W.J., Yang C.Y., Shao C.J., Hsu J.T., Lin R.M. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am 2005, 87(10):2155-2159.
93. Little D.G., McDonald M., Sharpe I.T., Peat R., Williams P., McEvoy T. Zoledronic acid improves femoral head sphericity in a rat model of Perthes disease. J Orthop Res 2005, 23:862-868.
94. Reitsma P.H., Bijvoet O.L.M., Verlinden-Ooms H., van der Wee-Pals L.J.A. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int 1980, 32:145-157.
95. Garnero P., Shih W.J., Gineyts E., Karpf D.B., Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994, 79:1693-1700.
96. Bauss F., Russell R.G.G. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004, 15:423-433.
97. Gasser J.A., Green J.R. Long-term protective effect of a single IV injection of zoledronic acid on cancellous bone structure and cortical bone in ovariectomized rats. Bone 2002, 30:41S. [suppl].
98. Sanders J.M., Ghosh S., Chan J.M., Meints G., Wang H., Raker A.M., et al. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem 2004, 47(2):375-384.
99. Thompson K., Rogers M.J. Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004, 19:278-288.
100. Ebetino F.H., Hogan A.M., Sun S., Tsoumpra M.K., Duan X., Triffitt J.T., et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011.
101. Ebrahimpour A., Francis M.D. Bisphosphonate therapy in acute and chronic bone loss: physical chemical considerations in bisphosphonate-related therapies. Bisphosphonate on bones 1995, Elsevier Science B.V. O. Bijvoet, H.A. Fleisch, R.E. Canfield, R.G.G. Russell (Eds.).
102. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 18:617-627.
103. Lawson M.A., Xia Z., Barnett B.L., Triffitt J.T., Phipps R.J., Dunford J.E., et al. Differences between bisphosphonates in binding affinities for hydroxyapatite. J Biomed Mater Res B Appl Biomater 2010, 92(1):149-155.
104. Trechsel U., Schenk R., Bonjour J.P., Russell R.G., Fleisch H. Relation between bone mineralization, Ca absorption, and plasma Ca in phosphonate-treated rats. Am J Physiol 1977, 232(3):E298-E305.
105. Shinoda H., Adamek G., Felix R., Fleisch H., Schenk R., Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 1983, 35:87-99.
106. Papapoulos S.E., Hoekman K., Lowik C.W.G.M., Vermeij P., Bijvoet O.L.M. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res 1988, 4:775-781.
107. Goa K.L., Balfour J.A. Risedronate. Drugs Aging 1998, 13:83-91.
108. Green J.R., Mueller K., Jaeggi K.A. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994, 9:745-751.
109. Ebetino F.H., Bayless A.V., Amburgey J., Ibbotson K.J., Dansereau S., Ebrahimpour A. Elucidation of a pharmacore for the bisphosphonate mechanism of bone antiresorptive activity. Phosphorus Sulfur Silicon 1996, 109/110:217-220.
110. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., et al. Bisphosphonate action. Alendronate localisation in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88:2095-2105.
111. Flanagan A.M., Chambers T.J. Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone. Bone Miner 1986, 6:33-43.
112. Ito M., Chokki M., Ogino Y., Satomi Y., Azuma Y., Ohta T., et al. Comparison of the cytotoxic effects of bisphosphnates in vitro and in vivo. Calcif Tissue Int 1998, 63:143-147.
113. Flanagan A.M., Chambers T.J. Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone. Bone Miner 1989, 6:33-43.
114. Breuil V., Cosman F., Stein L., Horbert W., Nieves J., Shen V., et al. Human osteoclast formation and activity in vitro: effects of alendronate. J Bone Miner Res 1998, 13:1721-1729.
115. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995, 10:1478-1487.
116. Selander K.S., Mönkkönen J., Karhukorpi E.-K., Härkönen P., Hannuniemi R., Väänänen H.K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996, 50:1127-1138.
117. Murakami H., Takahashi N., Sasaki T., Udagawa N., Tanaka S., Nakamura I., et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995, 17:137-144.
118. Hughes D.E., MacDonald B.R., Russell R.G.G., Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989, 83:1930-1935.
119. Boonekamp P.M., van der Wee-Pals L.J.A., van Wijk-van Lennep M.L.L., Wil Thesing C., Bijvoet O.L.M. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986, 1:27-39.
120. Löwik C.W.G.M., van der Pluijm G., van der Wee-Pals L.J.A., Bloys van Treslong-de Groot H., Bijvoet O.L.M. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res 1988, 3:185-192.
121. Masarachia P., Weinreb M., Balena R., Rodan G.A. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996, 19:281-290.
122. Azuma Y., Sato H., Oue Y., Okabe K., Ohta T., Tsuchimoto M., et al. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995, 16:235-245.
123. Sato M., Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990, 5:31-40.
124. Baron R., Ferrari S., Russell R.G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2010, 48(4):677-692.
125. Weinstein R.S., Roberson P.K., Manolagas S.C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009, 360(1):53-62.
126. Eisman J.A., Bone H.G., Hosking D.J., McClung M.R., Reid I.R., Rizzoli R., et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011, 26(2):242-251. 10.1002/jbmr.212.
127. Bellido T., Plotkin L.I. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 2010.
128. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104:1363-1374.
129. Plotkin L.I., Aguirre J.I., Kousteni S., Manolagas S.C., Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 2005, 280:7317-7325.
130. Plotkin L.I., Bivi N., Bellido T. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone 2010.
131. Sugiyama T, Meakin LB, Galea GL, Jackson BF, Lanyon LE, Ebetino FH, Russell RGG, Price JS. Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice. Bone this issue.
132. Fast D.K., Felix R., Dowse C., Neuman W.F., Fleisch H. The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochem J 1978, 172(1):97-107.
133. David P., Nguyen H., Barbier A., Baron R. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H+ ATPase. J Bone Miner Res 1996, 11:1498-1507.
134. Carano A., Teitelbaum S.A., Konsek J.D., Schlesinger P.H., Blair H.C. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990, 85:456-461.
135. Zimolo Z., Wesolowski G., Rodan G.A. Acid extrusion is induced by osteoclast attachment to bone. J Clin Invest 1995, 96:2277-2283.
136. Olpas E.E., Rutledge S.J., Golub E., Stern A., Zimolo Z., Rodan G.A., et al. Alendronate inhibition of protein-tyrosine-phosphatase-Meg1. Biochem Pharmacol 1997, 54:721-727.
137. Murakami H., Takahashi N., Tanaka S., Nakamura I., Udagawa N., Nakajo S., et al. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 1997, 20:399-404.
138. Felix R., Russell R.G.G., Fleisch H. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta 1976, 429:429-438.
139. Lerner U.H., Larsson A. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro. Bone 1987, 8:179-189.
140. Niskikawa M., Akatsu T., Katayama Y., Yasutomo Y., Kado S., Kugai N., et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996, 18:9-14.
141. Yu X., Scholler J., Foged N.T. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone 1996, 19:339-345.
142. Sahni M., Guenther H., Fleisch H., Collin P., Martin T.J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993, 91:2004-2011.
143. Vitte C., Fleisch H., Guenther H.L. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996, 137:2324.
144. Rogers M.J. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004, 75:451-461. [Review].
145. Rogers M.J., Watts D.J., Russell R.G.G., Ji X., Xiong X., Blackburn G.M., et al. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mould Dictyostelium discoideum. J Bone Miner Res 1994, 9:1029-1039.
146. Rogers M.J., Xiong X., Brown R.J., et al. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol Pharmacol 1995, 47:398-402.
147. Rogers M.J., Ji X., Russell R.G.G., Blackburn G.M., Williamson M.P., Bayless A.V., et al. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J 1994, 303:303-311.
148. Rogers M., Russell R.G.G., Blackburn G.M., Williamson M.P., Watts D.J. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem Biophys Res Commun 1992, 189:414-423.
149. Rogers M.J., Crockett J.C., Coxon F.P., Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2010.
150. Rogers M.J., Brown R.J., Hodkin V., Russell R.G.G., Watts D.J. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 1996, 224:863-869.
151. Pelorgeas S., Martin J.-P., Satre M. Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. Biochem Pharmacol 1992, 44:2157-2163.
152. Frith J.C., Mönkkönen J., Blackburn G.M., Russell R.G.G., Rogers M.J. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-b, g-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1996, 12:1358-1367.
153. Auriola S., Frith J., Rogers M.J., Koivuniemi A., Mönkkönen J. Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chromatogr B 1997, 704:187-195.
154. Frith J.C., Monkkonen J., Auriola S., Monkkonen H., Rogers M.J. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001, 44:2201-2210.
155. Rogers M.J., Xiong X., Ji X., Mönkkönen J., Russell R.G.G., Blackburn G.M., et al. Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonates is dependent on cellular uptake. Pharm Res 1997, 14:625-630.
156. Lehenkari P.P., Kellinsalmi M., Napankangas J.P., Ylitalo K.V., Monkkonen J., Rogers M.J., et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002, 61(5):1255-1262.
157. Amin D., Cornell S.A., Perrone M.H., Bilder G.E. 1-hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Drug Res 1996, 46:759-762.
158. Amin D., Cornell S.A., Gustafson S.K., Needle S.J., Ullrich J.W., Bilder G.E., et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 1992, 33:1657-1663.
159. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996, 65:241-269.
160. Konstantinopoulos P.A., Karamouzis M.V., Papavassiliou A.G. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007, 6(7):541-555. [Review].
161. Ridley A.J., Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992, 70:389-399.
162. Ridley A.J., Paterson H.F., Johnston C.L., Diekmann D., Hall A. The small GTP-binding protein, rac, regulates growth factor-induced membrane ruffling. Cell 1992, 70:401-410.
163. Zerial M., Stenmark H. Rab GTPases in vesicular transport. Curr Opin Cell Biol 1993, 5:613-620.
164. Zhang D., Udagawa N., Nakamura I., Murakami H., Saito S., Yamasaki K., et al. The small GTP-binding protein, Rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 1995, 108:2285-2292.
165. Luckman S.P., Hughes D.E., Coxon F.P., Russell R.G.G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589.
166. Luckman S.P., Coxon F.P., Ebetino F.H., Russell R.G.G., Rogers M.J. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998, 13:1668-1678.
167. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., Hughes D.E., Masarachia P.J., et al. Mechanism of action of alendronate: geranylgeraniol, an intermediate of the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci U S A 1999, 96:133-138.
168. van Beek E., Pieterman E., Cohen L., Löwik C., Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999, 255:491-494.
169. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296:235-242.
170. Kavanagh K.L., Guo K., Dunford J.E., Wu X., Knapp S., Ebetino F.H., et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. PNAS 2006, 103:7829-7834.
171. Staal A., Frith J.C., French M.H., Swartz J., Gungor T., Harrity T.W., et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 2003, 18:88-96.
172. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998, 279:509-514.
173. Smith R., Russell R.G.G., Woods C.G. Myositis ossificans progressiva. Clinical features of eight patients and their response to treatment. J Bone Joint Surg 1976, 58-B:48-57.
174. Smith R. Ectopic calcification and ossification. Chapter 31. Bisphosphonate on bones 1995, Elsevier Science B.V. O. Bijvoet, H.A. Fleisch, R.E. Canfield, R.G.G. Russell (Eds.).
175. Bijvoet O.L., Nollen A.J., Slooff T.J., Feith R. Effect of a diphosphonate on para-articular ossification after total hip replacement. Acta Orthop Scand 1974, 45(6):926-934.
176. Minaire P., Depassio J., Berard E., Meunier P.J., Edouard C., Pilonchery G., et al. Effects of clodronate on immobilization bone loss. Bone 1987, 8(Suppl 1):S63-S68. [Review].
177. Fogelman I., Bessent R.G., Turner J.F., Citrin D.L., Boyce I.T., Greig W.R. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med 1978, 19:270-275.
178. Francis M.D., Fogelman I. 99mTc-diphosphonate uptake mechanisms on bone. Bone scanning in clinical practice 1987, 1-6. Springer Verlag, London. I. Fogelman (Ed.).
179. Smith R., Russell R.G.G., Bishop M.C. Diphosphonates and Paget's disease of bone. Lancet 1971, i:945-947.
180. Russell R.G.G., Smith R., Preston C., Walton R.J., Woods C.F. Diphosphonates in Paget's disease. Lancet 1974, 1:894-898.
181. Frijlink W.B., Bijvoet O.L., te Velde J., Heynen G. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet 1979, 1(8120):799-803.
182. Johnston C.C., Khairi M.R., Meunier P.J. Use of etidronate (EHDP) in Paget's disease of bone. Arthritis Rheum 1980, 23(10):1172-1176.
183. Kanis J.A., Evanson J.M., Russell R.G.G. Paget's disease of bone: diagnosis and management. Metabolic bone disease & relation research 1981, 3:219-230.
184. Delmas P.D., Meunier P.J. The management of Paget's disease of bone. N Engl J Med 1997, 336:558-566.
185. Delmas P.D., Chapuy M.C., Vignon E., Charhon S., Briancon D., Alexandre C., et al. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab 1982, 54(4):837-844.
186. Meunier P.J., Chapuy M.C., Alexandre C., Bressot C., Edouard C., Vignon C., et al. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet 1979, 2(8141):489-492.
187. Reid I.R., Miller P., Lyles K., Fraser W., Brown J.P., Saidi Y., et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005, 353(9):898-908.
188. Grey A., Bolland M., Wattie D., Horne A., Gamble G., Reid I.R. Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial. J Bone Miner Res 2010, 25(10):2251-2255.
189. Hosking D., Lyles K., Brown J.P., Fraser W.D., Miller P., Curiel M.D., et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007, 22(1):142-148.
190. J Bone Miner Res 2007, 22(5):773. Erratum in:.
191. Reid I.R., Hosking D.J. Bisphosphonates in Paget's disease. Bone 2010.
192. Paterson A.D., Kanis J.A., Cameron E.C., Douglas D.L., Beard D.J., Preston F.E., et al. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. Br J Haematol 1983, 54:121-132.
193. Chapuy M.C., Meunier P.J., Alexandre C.M., Vignon E.P. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases. J Clin Invest 1980, 65(5):1243-1247.
194. van Breukelen F.J., Bijvoet O.L., van Oosterom A.T. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet 1979, 1(8120):803-805.
195. Coleman R.E., McCloskey E.V. Bisphosphonates in oncology. Bone 2011.
196. Clézardin P., Benzaïd I., Croucher P.I. Bisphosphonates in preclinical bone oncology. Bone 2010.
197. Watts N.B., Harris S.T., Genant H.K., et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990, 323:73-79.
198. Storm T., Thamsborg G., Steiniche T., et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990, 322:1265-1271.
199. van Staa T.P., Abenhain L., Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol 1998, 37:87-94.
200. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995, 333:1437-1443.
201. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
202. Bone H.G., Hosking D., Devogelaer J.-P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
203. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000, 11:83-91.
204. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344(5):333-340.
205. Chesnut C.H., Skag A., Christiansen C., Recker R.R., Stakkesatd J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
206. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356(18):1809-1822.
207. Kubo T., Shimose S., Matsuo T., Fujimori J., Ochi M. Minodronate for the treatment of osteoporosis. Drugs Today (Barc) 2010, 46(1):33-37.
208. Boonen S., Laan R.F., Barton I.P., Watts N.B. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005, 16:1291-1298.
209. Eastell R., Walsh J.S., Watts N.B., Siris E. Bisphosphonates for postmenopausal osteoporosis. Bone 2011.
210. McClung M.R., et al. BMD response to delayed-release risedronate 35mg once-a-week formulation taken with or without breakfast. J Clin Densitom 2010, 13:132. [Poster number 067; and Med Lett Drugs Ther. In brief: Delayed-release risedronate (Atelvia). 2011 Mar 21;53(1360):24].
211. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653-661.
212. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356(18):1809-1822.
213. Glorieux F.H., Bishop N.J., Plotkin H., Chabot G., Lanoue G., Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998, 33:947-952.
214. Rauch F., Glorieux F.H. Osteogenesis imperfecta, current and future medical treatment. Am J Med Genet C Semin Med Genet 2005, 139(1):31-37.
215. Lyles K.W., Colón-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zolendronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
216. Machado M., Cruz L.S., Tannus G., Fonseca M. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Clin Ther 2009, 31:962-979.
217. Bolland M.J., Grey A.B., Gamble G.D., Reid I.R. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010, 95:1174-1181.
218. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
219. Colon-Emeric C.S., Mesenbrink P., Lyles K.W., Pieper C.F., Boonen S., Delmas P., et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 2010, 25:91-97.
220. Clézardin P., Ebetino F.H., Fournier P.G. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005, 65:4971-4974.
221. Guenther A., Gordon S., Tiemann M., et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010, 126:239-246.
222. Varela I., Pereira S., Ugalde A.P., et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 2008, 14:767-772.
223. Chlebowski R.T., Chen Z., Cauley J.A., et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 2010, 28:3582-3590.
224. Sassa S., Okabe H., Nemoto N., Kikuchi H., Kudo H., Sakamoto S. Ibadronate may prevent colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Res 2009, 29:4615-4619.
225. Sewing L., Steinberg F., Schmidt H., Goke R. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 2008, 13:782-789.
226. Pazianas M., Abrahamsen B., Eiken P.A., Eastell R., Russell R.G.G. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate - Danish National Register Based Cohort Study. 37th European symposium on calcified tissues, Glasgow, Scotland 2010.
227. Beaupre L.A., Morrish D.W., Hanley D.A., Maksymowych W.P., Bell N.R., Juby A.G., et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 2011, 22:983-991.
228. Center J.R., Bliuc D., Nguyen N.D., Nguyen T.V., Eisman J.A. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 2011, 96:1006-1014.
229. Cree M.W., Juby A.G., Carriere K.C. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int 2003, 14:722-727.
230. Sambrook P.N., Cameron I.D., Chen J.S., March L.M., Simpson J.M., Cumming R.G., et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 2010, [Epub ahead of print].
231. Szabo C.M., Matsumura Y., Fukura S., Martin M.B., Sanders J.M., Sengupta S., et al. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem 2002, 45(11):2185-2196.
232. Artz J.D., Wernimont A.K., Dunford J.E., Schapira M., Dong A., Zhao Y., et al. Molecular characterization of a novel geranylgeranyl pyrophosphate synthase from Plasmodium parasites. J Biol Chem 2011, 286(5):3315-3322. [Epub 2010 Nov 17].
233. Artz J.D., Dunford J.E., Arrowood M.J., Dong A., Chruszcz M., Kavanagh K.L., et al. Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis. Chem Biol 2008, 15:1296-1306.
234. Ghosh S., Chan J.M., Lea C.R., Meints G.A., Lewis J.C., Tovian Z.S., et al. Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J Med Chem 2004, 47:175-187.
235. Martin M.B., Grimley J.S., Lewis J.C., Heath H.T., Bailey B.N., Kendrick H., et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J Med Chem 2001, 44(6):909-916.
236. Gabelli S.B., McLellan J.S., Montalvetti A., Oldfield E., Docampo R., Amzel L.M. Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design. Proteins 2005, 62(1):80-88. [Epub ahead of print].
237. Ling Y., Sahota G., Odeh S., Chan J.M., Araujo F.G., Moreno S.N., et al. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. J Med Chem 2005, 48(9):3130-3140.
238. Moreno B., Bailey B.N., Luo S., Martin M.B., Kuhlenschmidt M., Moreno S.N., et al. (31)P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth. Biochem Biophys Res Commun 2001, 284:632-637.
239. Rodriguez N., Bailey B.N., Martin M.B., Oldfield E., Urbina J.A., Docampo R. Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J Infect Dis 2002, 186(1):138-140.
240. Zhang S., Gangal G., Uludaǧ H. Magic bullets' for bone diseases: progress in rational design of bone-seeking medicinal agents. Chem Soc Rev 2007, 36:507-531. [Review].